Amarin Corp Plcuk (AMRN) Amortizatization of Intangibles (2012 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Amortizatization of Intangibles of $637000.0 for Q1 2026, down 47.62% YoY from $1.2 million in Q1 2025, and down 9.13% sequentially from $701000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Amortizatization of Intangibles across 15 years of filings, most recently posting $637000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 47.62% year-over-year to $637000.0; the TTM figure through Mar 2026 stood at $2.4 million (down 27.81% YoY), while the FY2025 annual figure was $3.0 million, up 4.28% from the prior year.
- Amortizatization of Intangibles eased to $637000.0 in Q1 2026, from $701000.0 in the prior quarter.
- Over the last five years, Amortizatization of Intangibles for AMRN reached as high as $2.0 million in Q2 2024 and fell as low as -$2.4 million in Q4 2022.
- The 5-year median for Amortizatization of Intangibles is $701000.0 (2023), against an average of $523117.6.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 342.51% — and 2024, when it slumped 280.17%.
- A 5-year view of Amortizatization of Intangibles shows it stood at -$2.4 million in 2022, then surged by 129.43% to $701000.0 in 2023, then tumbled by 280.17% to -$1.3 million in 2024, then surged by 155.5% to $701000.0 in 2025, then dropped by 9.13% to $637000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $637000.0, $701000.0, and $134000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 1.70 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 637,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 637,000.00 |
| Mar 31, 2026 | 637,000.00 |
| Dec 31, 2025 | 701,000.00 |
| Dec 31, 2025 | 701,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Jun 30, 2025 | 973,000.00 |
| Jun 30, 2025 | 973,000.00 |
| Mar 31, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | 729,000.00 |
| Mar 31, 2024 | 729,000.00 |
| Dec 31, 2023 | 701,000.00 |
| Dec 31, 2023 | 701,000.00 |